Trial Profile
A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
- Indications Malignant fibrous histiocytoma; Osteosarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Planned End Date changed from 1 Apr 2018 to 1 May 2019.
- 06 Jun 2017 Results of an integrated analysis assessing the effects of bevacizumab on growth/development in pediatric/adolescent patients (n=403), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology